Clinical Guidelines Portal
- What's New in the Guidelines
- Guidelines Panel Members
- Financial Disclosure
- Preconception Counseling and Care for HIV-Infected Women of Childbearing Age
- Antepartum Care
- Intrapartum Care
- Postpartum Care
- Appendix A: Review of Clinical Trials of Antiretroviral Interventions to Prevent Perinatal HIV Transmission
- Appendix B: Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
- Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Amprenavir (Agenerase, APV)
- Atazanavir (Reyataz, ATV)
- Darunavir (Prezista, DRV)
- Fosamprenavir (Lexiva, FPV)
- Indinavir (Crixivan, IDV)
- Lopinavir + Ritonavir (Kaletra, LPV/r)
- Nelfinavir (Viracept, NFV)
- Ritonavir (Norvir, RTV)
- Saquinavir (Invirase [Hard Gel Capsule], SQV)
- Tipranavir (Aptivus, TPV)
- Entry Inhibitors
- Integrase Inhibitors
- Antiretroviral Pregnancy Registry
- Appendix C: Acronyms
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States
Tipranavir (Aptivus, TPV)
(Last updated:3/28/2014; last reviewed:3/28/2014)
Tipranavir is classified as Food and Drug Administration Pregnancy Category C.
Animal Carcinogenicity Studies
Tipranavir was neither mutagenic nor clastogenic in a battery of five in vitro and animal in vivo screening tests. Long-term carcinogenicity studies in mice and rats have been conducted with tipranavir. Mice were administered 30, 150, or 300 mg/kg/day tipranavir, 150/40 mg/kg/day ritonavir-boosted tipranavir (TPV/r) in combination, or 40 mg/kg/day ritonavir. Incidence of benign hepatocellular adenomas and combined adenomas/carcinomas was increased in females of all groups except females given the low dose of tipranavir. Such tumors also were increased in male mice at the high dose of tipranavir and in the TPV/r combination group. Incidence of hepatocellular carcinoma was increased in female mice given the high dose of tipranavir and in both sexes receiving TPV/r. The combination of tipranavir and ritonavir caused an exposure-related increase in this same tumor type in both sexes. The clinical relevance of the carcinogenic findings in mice is unknown. Systemic exposures in mice (based on area under the curve [AUC] or maximum plasma concentration) at all dose levels tested were below those in humans receiving the recommended dose level. Rats were administered 30, 100, or 300 mg/kg/day tipranavir, 100/26.7 mg/kg/day TPV/r in combination, or 10 mg/kg/day ritonavir. No drug-related findings were observed in male rats. At the highest dose of tipranavir, an increased incidence of benign follicular cell adenomas of the thyroid gland was observed in female rats. Based on AUC measurements, exposure to tipranavir at this dose level in rats is approximately equivalent to exposure in humans at the recommended therapeutic dose. This finding is probably not relevant to humans because thyroid follicular cell adenomas are considered a rodent-specific effect secondary to enzyme induction.
Tipranavir had no effect on fertility or early embryonic development in rats at exposure levels similar to human exposures at the recommended clinical dose (500/200 mg/day of TPV/r).
No teratogenicity was detected in studies of pregnant rats and rabbits at exposure levels approximately 1.1-fold and 0.1-fold human exposure. Fetal toxicity (decreased ossification and body weights) was observed in rats exposed to 400 mg/kg/day or more of tipranavir (~0.8-fold human exposure). Fetal toxicity was not seen in rats and rabbits at levels of 0.2-fold and 0.1-fold human exposures. In rats, no adverse effects on development were seen at levels of 40 mg/kg/day (~0.2-fold human exposure), but at 400 mg/kg/day (~0.8-fold human exposure), growth inhibition in pups and maternal toxicity were seen.
The number of first-trimester exposures to tipranavir that have been monitored to date in the Antiretroviral Pregnancy Registry is insufficient to allow conclusions to be drawn regarding risk of birth defects.1
Placental and Breast Milk Passage
No animal studies of placental or breast milk passage of tipranavir have been reported. It is unknown if placental or breast milk passage of tipranavir occurs in humans.
Human Studies in Pregnancy
No studies of tipranavir have been completed in pregnant women or neonates. A case report with pharmacokinetic measurements of tipranavir used in a single pregnancy showed relatively high levels of tipranavir in the third trimester and relatively high placental transfer (0.41), as measured by cord blood.2 Whether this finding will be applicable to other pregnancies is unclear.
- Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 Jan 1989–31 July 2013. 2013. Available at http://www.APRegistry.com. Accessed March 5, 2014.
- Weizsaecker K, Kurowski M, Hoffmeister B, Schurmann D, Feiterna-Sperling C. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. Int J STD AIDS. 2011;22(5):294-295. Available at http://www.ncbi.nlm.nih.gov/pubmed/21571982.